|Bid||9.58 x 900|
|Ask||0.00 x 2200|
|Day's Range||8.98 - 9.59|
|52 Week Range||2.40 - 11.71|
|Beta (5Y Monthly)||1.77|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.83|
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery technology, is pleased to provide the following Letter to Shareholders from Chief Executive Officer Nadav Kidron.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery, announced today that randomization of patients in its first Phase 3 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D) is under way. The study is being conducted in accordance with U.S. Food and Drug Administration (FDA) approved protocols.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...